The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
D F Cella, D S Tulsky, G Gray...
https://pubmed.ncbi.nlm.nih.gov/8445433/Actively Recruiting
Led by Robert Olson · Updated on 2026-09-24
598
Participants Needed
14
Research Sites
4 weeks
Total Duration
Researchers are comparing two radiation therapy approachessingle fraction and multiple fraction stereotactic ablative radiotherapy SABRfor treating patients with 1 to 5 oligometastatic or oligo-progressive cancer lesions. This study aims to evaluate differences in treatment side effects, how long patients remain free from disease progression, quality of life, and cost-effectiveness. A subgroup will also examine the impact of healthcare provider-guided symptom management compared to questionnaire completion alone. Participants will be randomly assigned to receive either a single high-dose radiation treatment or multiple smaller doses spread over several sessions. Dosing varies by tumor location, including specific regimens for lung, bone, liver, spine, adrenal, lymph node, and brain lesions following institutional guidelines. In the subset of patients, quality of life questionnaires and symptom reporting will be used to guide healthcare interventions in one group while the other group completes questionnaires only. During the study, patients will complete quality of life assessments and symptom questionnaires at multiple time points up to five years post-treatment. Researchers will monitor adverse events, lesion control, progression-free survival, overall survival, and healthcare resource use. Radiation treatments follow a rigorous quality assurance process including CT simulation and organ contouring. The total study duration extends to approximately ten years, allowing long-term evaluation of outcomes and safety.
CONDITIONS
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
R
Robert Olson, MD, MSC, FRCPC
H
Hadassah Abraham, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Robert Olson
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies by participant
Participants receive either single fraction or multiple fraction stereotactic ablative radiotherapy based on random assignment. Radiation doses and schedules depend on tumor location and institutional protocols.
1 to several visits depending on treatment schedule
Duration - Up to 5 years
Participants complete quality of life questionnaires and symptom reporting at scheduled visits. Researchers monitor side effects, lesion control, progression-free survival, overall survival, and healthcare resource use for up to five years after treatment.
Multiple follow-up visits over 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
D F Cella, D S Tulsky, G Gray...
https://pubmed.ncbi.nlm.nih.gov/8445433/Timothy K Nguyen, Lee Chin, Arjun Sahgal...
https://pubmed.ncbi.nlm.nih.gov/34509549/Ethan Basch, Bryce B Reeve, Sandra A Mitchell...
https://pubmed.ncbi.nlm.nih.gov/25265940/Robert Olson, Lindsay Mathews, Mitchell Liu...
https://pubmed.ncbi.nlm.nih.gov/32370765/P H Patel, D Palma, F McDonald...
https://pubmed.ncbi.nlm.nih.gov/31182289/M Herdman, C Gudex, A Lloyd...
https://pubmed.ncbi.nlm.nih.gov/21479777/Kristin J Redmond, Scott Robertson, Simon S Lo...
https://pubmed.ncbi.nlm.nih.gov/27843035/S Hellman, R R Weichselbaum
https://pubmed.ncbi.nlm.nih.gov/7799047/Emma M Dunne, Arjun Sahgal, Simon S Lo...
https://pubmed.ncbi.nlm.nih.gov/31874346/Robert Olson, Hadassah Abraham, Curtis Leclerc...
https://pubmed.ncbi.nlm.nih.gov/38310262/Robert Olson
Lead Sponsor